Honorary President of the Chinese Pharmaceutical Enterprises Association
Yu Mingde is the Honorary President of the Chinese Pharmaceutical Enterprises Association. He has rich experience in medical production and distribution. Yu Mingde has served in roles of increasing responsibilities at the Fuxin Municipality Chemical Research Institute, Fuxin Pharmaceuticals Co., Ltd., Chinese Medicine Co., Ltd., as well as Director of the Fuxin Administration of Medical Products, and Director of Liaoning Province Administration of Medical Products. He also serves as Minister of Finance and Market Circulation for the National Administration of Medical Products, National Economy and Trade Administration, Minister of Medical Products, Deputy Director of the Economic Operations Bureau of the National Development and Reform Commission. Yu Mingde has also been invited to hold the position of Deputy Director of the Biomedical Expert Advisory Commission of the National Development and Reform Commission, as well as a member of the Major New Drug Panel of the Ministry of Science and Technology, the 13th Five Year Plan Panel of the Ministry of Industry and Information Technology, 09 Special Project Evaluation Panel of the Chinese Academy of Engineering. He is also a member of the advisory committee for the “Made in China 2025” plan.
Academician of the Chinese Academy of Sciences, Professor of the College of Chemistry, Nankai University
With a Ph.D in science, Zhou Qilin is a professor in the College of Chemistry at Nankai University, Cheung Kong Scholar of the Ministry of Education, and academician of the Chinese Academy of Sciences. His research interests include organic synthesis, organometallic chemistry, asymmetric catalysis, synthesis of bioactive compounds and chiral drugs. He discovered chiral spiro catalysts which show high activity and enantioselectivity in many asymmetric reactions, improving significantly the efficiency of the synthesis of chiral molecules. He was awarded the “Organic Synthesis Creation Award” by the Organic Chemistry Committee of the Chinese Chemical Society in 2005, the “Huang Yaozeng Organometallic Chemistry Award” by Chinese Chemical Society in 2006, the “Chiral Chemistry Award” by the Chinese Chemical Society in 2012. He was elected as a follow of the Royal Society of Chemistry in 2013. He won the Future Science Prize---Physical Science Prize in 2018 and the First Prize of the National Natural Science Award in 2019.
Former NMPA Chief Scientist, and FDA Senior Reviewer
Dr. Zengjun (Alex) Xu gained a bachelor’s degree in medicine in China and a PhD degree in Pharmacology and Toxicology in USA. He had his postdoctoral training at the National Center for Toxicological Research of the Food and Drug Administration (FDA). Dr. Xu worked at the Center for Drug Evaluation and Research of FDA (FDA/CDER) over 11 years as a Senior Reviewer in the Office of New Drugs (OND). He joined the Center for Drug Evaluation of NMPA (NMPA/CDE) in June 2017, as a Chief Scientist in the center for 3 years to promote the reform and improvement of the drug review system.
Special Vice President of the China Pharmaceutical Industry Association
Zhang Ziran, Ph.D. in Pharmaceutical Science, serves as Vice President of the China Pharmaceutical Industry Association, as well as Director of the Medical Policy and Regulation Committee, and Director of the Publicly Traded Pharmaceutical Companies Committee. He earned his master’s degree from West China University of Medical Sciences, followed by earning a doctoral degree at Shanghai University of Traditional Chinese Medicine, and pursued his MBA from the University of St Andrews, Scotland. Dr. Zhang established A&Z Pharmaceutical Inc. in the US and worked at Livzon Pharmaceutical Group Inc., Shanghai Pharma, and Shineway Pharma. following his return to China. He was an expert for the Drug Price Evaluation Center of National Development and Reform Commission.
President, Peking University School of Pharmaceutical Sciences
Dr. Zhou Demin is a professor and Dean of the School of Pharmaceutical Sciences, Peking University. He also serves as the Director of the State Key Laboratory of Natural and Biomimetic Drugs of China. He earned his bachelor’s degree from Beijing Medical University in 1990 and a joint Ph.D. degree from Beijing Medical University /University of Tsukuba, Japan in 1996. After 3 years teaching at the University of Tsukuba of Japan, Dr. Zhou went to the USA in 1999 for postdoctoral research at the University of California at Berkeley/The Scripps Research Institute. In 2002 he joined the American pharmaceutical industry, starting at Chugai-Roche as a senior scientist and then Immusol Inc. as a group leader and later division head. At the end of 2008, Dr. Zhou was recruited by Peking University as a full professor in China. He is currently a Yangtze River Scholars Distinguished Professor and the leading scientist for one of China’s “973 Project” His research area is to develop new chemicals and biotechnologies, based on integration of chemistry and biology, for improvement of the targeting and efficiency of anti-virus and anti-cancer drugs. The discovery of the “conversion of an infectious virus into a live-but-replication incompetent virus vaccine” has been named as “Paper of the Year” of the International Vaccine Society. Dr. Zhou serves as Associate Editor of Molecular Pharmaceutics and on the editorial board for several international journals including J Med Chem, Eur J Med Chem and Inter J Virology & AIDS.
Professor at Shanghai Jiao Tong University
Dr. Zhu has been awarded as Distinguished Expert of China since 2011 and appointed as “Zhi Yuan” Chair Professor, and Director of the Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, China. He received the “2017 National Award of Promoting Industry-University-Institute Collaboration”. Dr. Zhu received his degrees in biochemical engineering, microbial genetics, and MBA in China and the United States, then he spent his post-doctoral research at MIT and Harvard Medical School to develop his expertise for the career in biopharmaceutical development. Since 1987, Dr. Zhu played technical leadership roles 33 years, including 17 years with the Biopharmaceutical Development Program at Frederick National Laboratory for Cancer Research as director of technical operation.
Co-Chief Investment Officer & a partner at Hillhouse Capital Group
Michael Yi has been working with Hillhouse since the inception of the firm in 2005. Mr. Yi leads Hillhouse Capital’s healthcare investments in both public and private equities. He and his team have successfully invested in a great number of public companies. On private investment, his team has made investments into healthcare companies including Wuxi AppTec, BeiGene, Innovent, Junshi Biosciences, Ganlee, and dozens of innovative start-ups in biomedicine and medical devices in China and the United States, in addition to establishing Huimei Healthcare, a JV between Hillhouse and Mayo Clinic in China, in order to creating a “people-oriented ecosystem, focusing on support for innovative healthcare”. He holds an MBA from the Marshall School of Business at University of Southern California.
Corporate Vice President for Covance and General Manager for Covance China
Dr. Bi Honggang is a Ph.D. in chemistry and drug metabolism, Corporate Vice President for Covance and General Manager for Covance China. He is responsible for leading all Covance business and service activities in China including preclinical and clinical development, as well as central laboratory services; and representing Covance with various Chinese regulatory and government agencies. Since joining Covance in 2007, Dr. Bi has led the rapid growth of Covance China, expanding service offerings for local, regional and global clients. Dr. Bi has served in various leadership positions at various pharmaceutical companies such as SmithKline Beecham, Parke-Davis and Pfizer. Dr. Bi’s scientific achievements can be evidenced by more than 30 research publications and various presentations at scientific conferences.
Prof. Jin-Quan Yu
Professor of Scripps Institute, Fellow of the American Academy of Arts and Sciences, Professor of Chemistry of Frank and Bertha Hepp in 2012, and currently the leader of C-H bond activation research in international frontier disciplines. He obtained a bachelor degree from East China Normal University in 1987, a master degree in chemistry from Guangzhou Institute of Chemistry in 1990, a doctorate from Cambridge University in the United Kingdom in 1999 and entered Harvard University in 2000 for a two-year postdoctoral research. Professor Yu has successively served as an assistant professor in the Royal Society Research Institute at Cambridge University and Brandeis University, and as an associate professor at the Scripps Institute. He has published more than 200 high-quality papers, holds 26 patents, and won the 2017 Royal Chemical Society Pedler Award , 2016 MacArthur Genius Award, 2014 Elias J. Corey Award, 2012 ACS Arthur Science Scholar Award, 2009 China-US Association of Professors of Chemistry and Chemical Biology "Outstanding Professor Award", etc.
Prof. Phil Baran
Professor of the Scripps Institute, Fellow of the National Academy of Sciences of the US, Fellow of the American Academy of Sciences and the Arts, and one of the most famous young organic chemists nowadays.
He received a bachelor degree with honors from New York University in 1997, and a Ph.D. from the Scripps Institute in 2001. He then conducted a two-year postdoctoral study at Harvard University under the guidance of Professor E.J. Corey. Professor Baran has published more than 200 high-quality papers and has 15 core patents. He has won numerous honors and awards, such as the Inhoffen Medal in 2019, the ACS Elias J. Corey Award in 2016, the MacArthur Genius Award in 2013 and 2013 Royal Society of Chemistry Award for Organic Synthetic Chemistry. At the same time, Professor Baran is also a consultant for many large multinational companies, such as BMS (Bristol-Myers Squibb), DuPont (DuPont United States) and Boehringer-Ingelheim ( and so on.
Prof. Stephen L. Buchwald
Chief Professor of Chemistry at the Massachusetts Institute of Technology, Fellow of the American Academy of Arts and Sciences, and Fellow of the National Academy of Sciences. He has published 490 papers and 47 granted patents.
2000 Organic Metal Chemistry Award from American Chemical Society and MERIT Award from National Institutes of Health. He won the Bristol-Myers Squibb Award for Outstanding Achievement and CAS Science Focus Award in 2005, the Creative Work Award of the American Chemical Society for Synthetic Organic Chemistry, and the Siegfried Chemical Method Medal. Gustavus J. Esselen's 2010 Public Chemical Chemistry Award. 2013 Arthur C. Cope Award from the American Chemical Society. 2014 Linus Pauling Medal and Ulysses Medal (University of Dublin). He received an honorary doctorate from the University of South Florida in 2015 and also won the BBVA Basic Science Knowledge Award (2014 Award). Selected as the recipient of the 2016 William H. Nichols Medal and the 2018 Roger Adams Award for Organic Chemistry.
Prof. Nicholas Turner
Professor of the University of Manchester. He is one of the best experts in "making better enzymes" in the world, and has published nearly 40 papers.
Research fields: biocatalytic organic synthesis research; directed evolution of enzymes; protein process technology; design and synthesis of small molecule therapeutic protein inhibitors; development of biomass-to-biofuel technology.
Royal Society Wolfson Research Award (2011). RSC Organic Industrial Chemistry Award (2009); AZ / GSK / Prizer British Process Chemistry Research Award (2007); International Biocat Award (2004); Royal Society of Chemistry Cody-Morgan Medal and Winner (1996); Pfizer Organic Scholarship in Chemistry (1995); Carbohydrate Chemistry Medal of the Royal Society of Chemistry (1992); Royal Society Fullerton Gift and Binmore Kenner Junior Research Scholarship (1987).
Dr. Martin Eastgate
As the executive director of Bristol-Myers Squibb, Dr. Eastgate is experienced in scientific research and development and organizational leadership. With management of domestic teams and multinational teams, he is also responsible for BMS setting company product programs and developing disruptive innovation science.
Dr. Eastgate graduated from the University of Cambridge and worked with Dr. Stuart Warren on sulfur mediated, stereocontrolled, heterocycle synthesis; he had his post-doctoral research on Lewis-base mediated activation of Lewis-acids in collaboration with Professor Scott Denmark at the University of Illinois at Urbana-Champaign, The concept is applied in catalytic asymmetric transformation. He has published 70 papers and thesis, holds 9 patents and has won 8 awards, including Industrial Organic Chemistry Award, FRSC Fellow, International Society of Heterocyclic Chemistry Industrial Chemistry Award, Lecturer of McElvain, ACS Young Researcher, GlaxoSmithKline Postdoctoral Scholarship in Organic Chemistry, Syngenta Graduate Scholarship in Organic Chemistry, Margaret Evic Margaret Excellence Award in Organic Chemistry, etc.
Dr. Stephane Caron
As vice president of chemical process research and development of Pfizer, he is responsible for the discovery, development and commercialization of new drugs.
He obtained a master degree from Laval University in France in 1991 and a doctorate degree from the University of California, Berkeley in 1995. After that, he joined Pfizer in chemical process research and development. From the position of basic personnel in research and development to senior management, Dr. Caron has extensive experience in research and development and management. He has published more than 40 papers, 16 authorized patents, and holds positions in a number of international scientific organizations, such as: Member of the Canadian Natural Science and Engineering Technology Research Council 2003-2006, Member of the ACS Editor Selection Committee 2016, Organic Process Member of the editorial board of the Organic Process Research and Development journal.
Prof. Timothy F. Jamison
Associate Dean of Massachusetts Institute of Technology, Professor of Chemistry Robert R. Taylor, Co-founder, Chairman and Scientific Adviser of Snapdragon Chemistry, Member of the Royal Society of Chemistry.
He received his master degree from the University of California, Berkeley College in 1990 and his Ph.D. from Harvard University in 1997. Professor Jamison has published a number of core papers and books. He is also a member of the editorial board of the Journal of Flow Chemistry, a member of the Academic Advisory Board of the journal Advanced Synthesis and Catalysis, and Associate Editor of the Chemistry Review. Professor Jamison has won the 2011 Arthur Science Scholar Award from the American Chemical Society, the 2012 Merck Award from the Royal Society of Chemistry, the 2013 MIT Undergraduate Education Teaching Award, and the 2018 MIT Reformer Title IX Award.
Dr. Seble Wagaw
As the senior director of AbbVie Pharmaceuticals and head of organic synthesis and process development, she has 20 years of R & D and management experience at AbbVie.
Dr. Wagaw received a master degree from the University of Michigan in 1994 and a Ph.D. from the Massachusetts Institute of Technology in 1999. She then joined AbbVie, where she has extensive experience in R & D and management, from basic R & D staff to senior management. Dr. Wagaw is the co-founder of the AbbVie Women's Chemical Group, the co-founder of the Cross-industry Women's Chemical Process Group. She also won the 2013 ACS New Women's Award for Chemistry. At the same time, as a female elite in the industry, Dr. Wagaw was invited by various well-known universities and social organizations to deliver many professional lectures.
Dr. Scott A. May
Dr. May graduated from Hope College with a master degree in 1993. He graduated with a PhD in organic chemistry from Indiana University in 1998. He joined Eli Lilly's process R & D group as a senior organic chemist and is currently a researcher at RNA Therapeutics. Responsible for overall R & D and CMC work.
He has more than 20 years of experience in the synthesis design, material delivery and process development of new drug candidates, and has extensive experience from preclinical to advanced clinical trials. He has a strong capability of interdisciplinary collaboration in chemistry research discovery, analysis, formulations, regulations, quality and process engineering.
Expertise: synthetic organic chemistry, route selection, continuous processing, continuity, asymmetric catalysis, heterogeneous catalysis, route development, process enhancement, new technologies and regulations CMC, RNA Therapeutics, oligonucleotide synthesis, solid phase synthesis
Executive Producer of Healthcare Executive magazine series
Tan Yong started his career in medical media and information services in 2003. Now he is the producer of “Healthcare Executives” and “China County Health”, Secretary General of the China Healthcare Investment 50 Forum. Previously, he was the Deputy Editor in chief of “Medicine Economic Reporter”. Tan Yong is the author of “Main Stream-Wisdom of the China pharmaceutical Entrepreneurs” and “The Trilogy of Empowering China's Pharmaceutical Industry Transformation and Upgrading”. Tan Yong also oversaw the publishing of the book series “China's Pharmaceutical Industry Opinion Leader Papers”, which included “Aim at the First Legion of the China Pharmaceutical Industry”, “China Pharmaceutical Industry Reflections”, and “Apocalypse of the Pharmaceutical Giants”.
Dr. Patricia A. Alred
President of Patricia Alred Consulting, specialist in market operations and biomolecular development. She has more than 20 years of extensive experience in research and development and commercial production, As a technical expert in both biotechnology development and production, she has extensive experience in clinical and commercial pharmaceutical product medical auditing and archiving; she also has a good understanding of lean culture.
Dr. Alred graduated with a PhD degree from Lund University, Sweden in 1993, and conducted post-doctoral research at the Massachusetts Institute of Technology from 1993 to 1995. Her research area is chemical engineering. She has worked in Bayer, Medlmmune, GlaxoSmithKline, Johnson & Johnson and other companies.
Involved areas: All aspects of biological R & D and commercial production, including medical and health GMP inspections of commercial products, and submission of new products BLA / MAA. She has developed standardized vision factories for pharmaceuticals, consumers and MD & D manufacturing, and conducted trials in 9 internal and external production sites and implemented them in Malvern.